logo

Diffusion Pharmaceuticals Inc. ( (DFFN)



Trade DFFN now with
  Date
  Headline
7/23/2019 8:43:35 AM Diffusion Reports Favorable Safety Data For Dose-Escalation Run-in Of Phase 3 INTACT Study
12/17/2018 9:57:16 AM US Patent Office Awards Diffusion Rights For Use Of TSC In Conjunction With Only FDA-Approved Stroke Therapeutic
11/14/2018 9:06:44 AM Diffusion Pharma Q3 Loss/shr $0.13 Vs. EPS $0.20 Prior Year
9/12/2018 9:05:01 AM FDA Oks Start Of Innovative On-Ambulance Phase 2 Trial For Treatment Of Acute Stroke By Diffusion Pharma
8/13/2018 8:34:57 AM Diffusion Pharma H1 Net Cash Used In Operating Activities $5.8 Mln Vs $6.2 Mln Last Year
6/12/2018 8:43:54 AM Diffusion Pharma Announces Validation Of European Patent For Oral Formulations Of TSC
2/1/2018 8:15:43 AM Diffusion Announces Allowances Of Two U.S. Patent Applications
1/18/2018 6:01:52 AM Diffusion Pharma Prices Underwritten Public Offering Of 15 Mln Common Shares At $0.80/Shr
1/10/2018 8:52:20 AM Orphan Rare Diseases R&D Advancements Increase Novel Therapeutic Options For Drug Development Pipeline
  
 
>